Matthew P. Goetz

Matthew P. Goetz, M.D., is a Professor of Oncology and Pharmacology at the Mayo Clinic. He holds roles as a Consultant in the Division of Medical Oncology and Enterprise Deputy Director of Translational Research at the Mayo Clinic Comprehensive Cancer Center. His research focuses on estrogen receptor-positive breast cancer, novel therapeutics for endocrine-resistant cancers, and pharmacogenetics of tamoxifen. Key contributions include leading the development of endoxifen hydrochloride and co-leading the Breast Cancer Genome-Guided Therapy (BEAUTY) study.

• Education: MD from University of North Dakota School of Medicine; Postdoctoral Fellowship in Hematology/Oncology at Mayo Graduate School.
• Research Highlights: BEAUTY study (funded by Mayo Clinic Center for Individualized Medicine), pharmacogenomics of tamoxifen, and clinical trials for endocrine therapies.
• Awards: Erivan K. Haub Family Professorship (2020), Team Science Award (2019), and recognition as a Top Oncologist (2021).

His work integrates genomic sequencing, patient-derived xenografts, and translational research to improve outcomes for high-risk breast cancer patients. Dr. Goetz collaborates with the NIH and NCI, leading initiatives in pharmacogenomics and breast cancer drug development.